EGFR and non-small cell lung carcinoma: Kanthala et al. designed peptide inhibitors that inhibit the formation of HER2:HER3 and EGFR:HER2 heterodimers by disrupting protein-protein interactions and demonstrated inhibition of tumor proliferation in NSCLC cells and synergistic effects with erlotinib18.